2.5.1.21 (1-[[(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidin-4-yl)acetic acid - 88675 2.5.1.21 (1-[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl)acetic acid i.e. lapaquistat acetate or TAK-475 42321 2.5.1.21 (1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl)acetic acid - 88653 2.5.1.21 (1-[[(6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetyl]piperidin-4-yl)acetic acid - 88659 2.5.1.21 (1R,5S)-7-chloro-5-(2-methoxyphenyl)-1-(2-methylpropyl)-3-[2-oxo-2-(piperidin-1-yl)ethyl]-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one - 88677 2.5.1.21 (2E)-3-[(1R,5S)-3-(carboxymethyl)-7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]-2-methylprop-2-enoic acid - 88667 2.5.1.21 (3R)-3-[[3-(benzyloxy)phenyl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol IC50: 1500 nM 61655 2.5.1.21 (3S)-1-(3-((4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)propanoyl)-3-piperidine carboxylic acid - 88628 2.5.1.21 (3S)-1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-3-piperidinecarboxylic acid - 88618 2.5.1.21 1,3-diallyl-2-[3-(isopropylamino)propoxy]-9H-carbazole 50% inhibition at 250 nM 124873 2.5.1.21 1-(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-2H-1,2,3,4-tetrazol-5-yl)cyclopropanecarboxylic acid - 88651 2.5.1.21 1-(3-((4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)propanoyl)-3-azetidine carboxylic acid - 88629 2.5.1.21 1-allyl-2-(3-anilinopropoxy)-9H-carbazole 50% inhibition at above 0.001 mM nM 124880 2.5.1.21 1-allyl-2-[3-(benzylamino)propoxy]-9H-carbazole 50% inhibition at 63 nM 124877 2.5.1.21 1-allyl-2-[3-(benzylamino)propoxy]-9H-carbazole hydrochloride 50% inhibition at 150 nM 125149 2.5.1.21 1-allyl-2-[3-(cyclohexylamino)propoxy]-9H-carbazole 50% inhibition at 310 nM 124879 2.5.1.21 1-allyl-2-[3-(cyclopropylamino)propoxy]-9H-carbazole 50% inhibition at 230 nM 124878 2.5.1.21 1-allyl-2-[3-(isobutylamino)propoxy]-9H-carbazole 50% inhibition at 400 nM 124876 2.5.1.21 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole 50% inhibition at 32 nM 56729 2.5.1.21 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole 50% inhibition at 66 nM 56729 2.5.1.21 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one 50% inhibition at 120 nM 56730 2.5.1.21 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinecarboxylic acid - 88617 2.5.1.21 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazole-4-carboxylic acid - 88636 2.5.1.21 1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-pyrazole-4-carboxylic acid - 88644 2.5.1.21 1-[[(1R,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidine-4-carboxylic acid - 42322 2.5.1.21 1-[[(1R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidine-4-carboxylic acid - 88679 2.5.1.21 1-[[(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidine-4-carboxylic acid - 88676 2.5.1.21 1-[[(1R,5S)-7-chloro-5-(2-methoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidine-4-carboxylic acid - 88678 2.5.1.21 1-[[(1S,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]piperidine-4-carboxylic acid - 88680 2.5.1.21 1-[[(6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetyl]piperidine-4-carboxylic acid - 88660 2.5.1.21 11,12-di-O-methylcarnosol - 253001 2.5.1.21 11,12-diacetyl-carnosol - 253002 2.5.1.21 2-(1-(3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl)-3-azetidinyl)acetic acid - 88630 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid - 88616 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazol-4-yl)acetic acid - 88637 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazol-5-yl)acetic acid - 88638 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-pyrazol-3-yl)acetic acid - 88642 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-pyrazol-4-yl)acetic acid - 88645 2.5.1.21 2-(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-pyrazol-5-yl)acetic acid - 88643 2.5.1.21 2-(1-[2-[(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid - 88615 2.5.1.21 2-(1-[2-[8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid - 88611 2.5.1.21 2-(1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-4-piperidinyl)acetic acid - 88627 2.5.1.21 2-(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)ethyl]-2H-1,2,3,4-tetrazol-5-yl]-2-methylpropanoic acid - 88650 2.5.1.21 2-(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)ethyl]-2H-1,2,3,4-tetrazol-5-yl]acetic acid - 88647 2.5.1.21 2-(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3,4-tetrazol-5-yl)acetic acid - 88648 2.5.1.21 2-(4-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]-1-piperazinyl)acetic acid - 88619 2.5.1.21 2-(4-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-2-oxo-1-piperazinyl)acetic acid - 88635 2.5.1.21 2-(trans-4-stilbenyl)-4-methyl-morpholin-2-ol - 253004 2.5.1.21 2-([2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]amino)acetic acid - 88620 2.5.1.21 2-[(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazol-4-yl)methoxy]-2-ethylbutanoic acid - 88641 2.5.1.21 2-[(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazol-4-yl)methoxy]-2-methylpropanoic acid - 88640 2.5.1.21 2-[(1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-1H-1,2,3-triazol-4-yl)methoxy]acetic acid - 88639 2.5.1.21 2-[(1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-4-piperidinyl)methoxy]acetic acid - 88633 2.5.1.21 2-[(1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-4-piperidinyl)oxy]acetic acid - 88631 2.5.1.21 2-[(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-2H-1,2,3,4-tetrazol-5-yl)methoxy]-2-methylpropanoic acid - 88652 2.5.1.21 2-[(6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]-1-[(3R)-3-hydroxypyrrolidin-1-yl]ethanone - 88658 2.5.1.21 2-[1,8-dichloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88612 2.5.1.21 2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-2H-1,2,3,4-tetrazol-5-carboxylic acid - 88646 2.5.1.21 2-[3-(isopropylamino)propoxy]-1-ethyl-9H-carbazole 50% inhibition at 460 nM 124874 2.5.1.21 2-[3-(isopropylamino)propoxy]-9H-carbazole 50% inhibition at 810 nM 57025 2.5.1.21 2-[3-(isopropylamino)propoxy]-9H-carbazole 50% inhibition at 110 nM 57025 2.5.1.21 2-[8-chloro-6-(1-naphthyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88623 2.5.1.21 2-[8-chloro-6-(2,3-dichlorobenzoyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88624 2.5.1.21 2-[8-chloro-6-(2,3-dihydro-1,4-benzodioxin-5-yl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88625 2.5.1.21 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-(4-morpholinylmethyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88614 2.5.1.21 2-[8-chloro-6-(2,3-dimethoxyphenyl)-1-[(dimethylamino)methyl]-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88613 2.5.1.21 2-[8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetic acid - 88610 2.5.1.21 2-[[(2Z)-2-(1-azabicyclo(2.2.2)oct-3-ylidene)-2-fluoroethyl]oxy]-9H-carbazole i.e. YM-53601, 50% inhibition at 90 nM 125148 2.5.1.21 3-(2-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl]-2H-1,2,3,4-tetrazol-5-yl)propanoic acid - 88649 2.5.1.21 3-(4-quinolin-6-ylphenyl)quinuclidin-3-ol i.e. RPR107393, 50% inhibition at 57 nM 56731 2.5.1.21 3-(4-quinolin-6-ylphenyl)quinuclidin-3-ol i.e. RPR107393, 50% inhibition at 68 nM 56731 2.5.1.21 3-(biphenyl-4-yl)-2,3-dehydroquinuclidine 50% inhibition at 243 nM 124883 2.5.1.21 3-(biphenyl-4-yl)-3-hydroxyquinuclidine 50% inhibition at 13 nM 124881 2.5.1.21 3-(biphenyl-4-yl)-4'[(t-butyldimethylsilyl)oxy]-3-hydroxyquinuclidine 50% inhibition above 0.001 mM 124882 2.5.1.21 3-(biphenyl-4-yl-4'-hydroxy)-2,3-dehydroquinuclidine 50% inhibition at 96 nM 124884 2.5.1.21 3-(biphenyl-4-ylmethyl)-1-azabicyclo[2.2.2]oct-2-ene IC50: 730 nM 61653 2.5.1.21 3-(trans-4-stilbenyl)octahydropyridino[2,1-c][1,4]oxazin-3-ol - 253005 2.5.1.21 3-([2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]amino)benzoic acid - 88622 2.5.1.21 3-([2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]amino)propionic acid - 88621 2.5.1.21 3-C-carboxy-2,4-dideoxy-2-dodec-11-en-1-ylpentaric acid - 154838 2.5.1.21 3-C-carboxy-2,4-dideoxy-2-dodecylpentaric acid - 154839 2.5.1.21 3-[(1-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-4-piperidinyl)oxy]propanoic acid - 88632 2.5.1.21 3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6Hpyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propionic acid - 88626 2.5.1.21 3-[[4-(benzyloxy)phenyl]ethynyl]-1-azabicyclo[2.2.2]oct-2-ene IC50: 830 nM 61654 2.5.1.21 4-methyl-2-(3',5'-di-tert-butyl-4'-hydroxy-4-biphenyl)-3,4-dihydro-2H-1,4-benzothiazine-2-ol - 253006 2.5.1.21 4-methyl-2-(4'-hydroxybiphenyl)-3,4-dihydro-2H-1,4-benzothiazin-2-ol - 253007 2.5.1.21 4-methyl-2-(4'-trifluromethyl-4-biphenyl)-3,4-dihydro-2H-1,4-benzothiazine-2-ol - 253008 2.5.1.21 4-methyl-2-phenyl-3,4-dihydro-2H-benzothiazin-2-ol - 253009 2.5.1.21 4-methyl-2-phenyl-3,4-dihydro-2H-benzoxazin-2-ol - 253010 2.5.1.21 4-[3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl]-2-morpholine carboxylic acid - 88634 2.5.1.21 6-([[(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl]amino)hexanoic acid - 88674 2.5.1.21 7alpha-ethoxyrosmanol - 252995 2.5.1.21 7alpha-methoxyrosmanol - 252994 2.5.1.21 Ammonium analogues overview 98383 2.5.1.21 atorvastatin - 4365 2.5.1.21 BMS 187745 decrease of cholesterol or LDL 155449 2.5.1.21 BMS-187745 - 135462 2.5.1.21 BMS-188494 - 24426 2.5.1.21 BMS-188494 decrease of cholesterol or LDL 24426 2.5.1.21 BMS-188494 no induction of myotoxicity 24426 2.5.1.21 BPH-652 a phosphonosulfonate, binding structure 212880 2.5.1.21 BPH-652 potent inhibitor 212880 2.5.1.21 BPH-701 about 60% inhibition at 0.005 mM 212881 2.5.1.21 carnosol - 163532 2.5.1.21 carnosol quinone - 252999 2.5.1.21 celastrol binds to the enzyme in a noncompetitive manner, but does not bind covalently. Celastrol also inhibits growth of the highly virulent Aspergillus fumigatus by inhibiting flavin-dependent monooxygenase siderophore A , it may be a promising multi-target lead for antifungal development 14703 2.5.1.21 chlorogenic acid - 592 2.5.1.21 CHQHNSMYC an ennea-peptide, slight inhibition 212899 2.5.1.21 CKTE a tetrapeptide 212886 2.5.1.21 CKTENMQSC an ennea-peptide 212900 2.5.1.21 CLGV a tetrapeptide 212888 2.5.1.21 CLGVHSSSC an ennea-peptide 212897 2.5.1.21 CLSPHSMFC an ennea-peptide 212896 2.5.1.21 CP-294838 a benzoxazepinone IC50 130 nM 50674 2.5.1.21 CP-295697 a bisphosphonate, IC50: 20 nM 50675 2.5.1.21 CP-320473 - 212882 2.5.1.21 CP-424677 - 212884 2.5.1.21 CP-458003 - 212883 2.5.1.21 CPWW a tetrapeptide 212890 2.5.1.21 CQMHQLSSC an ennea-peptide 212894 2.5.1.21 CSGMKTTGC an ennea-peptide 212895 2.5.1.21 CSTLKVATC an ennea-peptide 212901 2.5.1.21 CSTPWHQWC an ennea-peptide 212898 2.5.1.21 CTVNWYPLC an ennea-peptide 212902 2.5.1.21 cynarin by the combination of three different computational approaches and biological assays, cynarin is selected as a potential squalene synthase inhibitor 58947 2.5.1.21 deoxycholate - 441 2.5.1.21 E5700 IC50: 0.84 nM 62507 2.5.1.21 EP2302 - 36402 2.5.1.21 EP2302 decrease of cholesterol or LDL 36402 2.5.1.21 EP2302 decrease of cholesterol and triglyceride biosynthesis 36402 2.5.1.21 EP2306 decrease of cholesterol or LDL 77413 2.5.1.21 EP2306 decrease of cholesterol and triglyceride biosynthesis 77413 2.5.1.21 ER-27856 - 36401 2.5.1.21 ER-27856 decrease of cholesterol biosynthesis 36401 2.5.1.21 ER-28448 decrease of cholesterol biosynthesis 77412 2.5.1.21 ER119884 IC50: 3.52 nM 62508 2.5.1.21 ethyl 4-(1-azabicyclo[2.2.2]oct-2-en-3-yl)benzoate IC50: 50 nM 61652 2.5.1.21 ethyl [(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetate - 88663 2.5.1.21 farnesyl diphosphate no inhibition of presqualene diphosphate synthase reaction; substrate inhibitor of squalene synthase reaction 171 2.5.1.21 farnesyl diphosphate substrate inhibitor of squalene synthase reaction 171 2.5.1.21 Farnesyl methylenediphosphonate a substrate analogue, potent enzyme inhibition 44126 2.5.1.21 fenofibrate - 6805 2.5.1.21 galdosol - 252996 2.5.1.21 Guanidinium chloride loss of 86% activity at 0.3M GdmCl, 50% at 0.2 M 2558 2.5.1.21 isorosmanol - 252998 2.5.1.21 KTTG a tetrapeptide 212891 2.5.1.21 lapaquistat lipid-lowering effect 19112 2.5.1.21 lapaquistat decrease of cholesterol or LDL 19112 2.5.1.21 LSPH a tetrapeptide 212892 2.5.1.21 methyl 2-[8-chloro-6-(2,3-dimethoxyphenyl)-4H,6Hpyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetate - 88609 2.5.1.21 Mg2+ above 35 mM 6 2.5.1.21 additional information peroxisomal squalene synthase is inhibited by sonication, microsomal enzyme not 2 2.5.1.21 additional information identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors, overview 2 2.5.1.21 additional information 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as squalene synthase inhibitors, design, synthesis, structure-activity relationship, and pharmacological profiles, overview 2 2.5.1.21 additional information design, synthesis, and identification of highly potent benzhydrol derivatives as squalene synthase inhibitors, design of tricyclic pyrrolobenzoxazepine derivatives, overview 2 2.5.1.21 additional information discovering peptide inhibitors of human squalene synthase through screening the phage-displayed cyclic peptide c7c library, molecular modelling and ADMET predictions of the selected peptides, using the crystal structure PDB 1EZF, a homo-trimer protein complex (with inhibitors CP-320473, CP-458003 and CP-424677), as the target, overview. The inhibitory peptides have potentials to develop cholesterol-lowering therapeutics. The ligand-protein interaction analysis also reveals that the inner hydrophobic pocketis a critical site of human enzyme for inhibition. No binding of peptide CPWWYGPWC. Cytotoxicity effects of different inhibitors, and protein-ligand interaction analysis, overview 2 2.5.1.21 additional information overexpression of the enzyme's C-terminal domain containing a hinge domain from fungi, not from animals or plants, leads to growth inhibition of wild-type yeast 2 2.5.1.21 additional information evaluation of the structure of substrate/inhibitor-binding sites via homology modeling, overview. Supplementation of any type of detergent inhibits the enzyme activity during purification 2 2.5.1.21 N-ethylmaleimide - 49 2.5.1.21 N-isopropyl-biphenyloxypropylamine 50% inhibition at 93 nM 124875 2.5.1.21 N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]-L-aspartic acid - 172022 2.5.1.21 NADP+ inhibitor of squalene synthesis 10 2.5.1.21 rosmadial - 252997 2.5.1.21 rosmanol - 252993 2.5.1.21 rosmaquinone - 253000 2.5.1.21 RPR107393 reduction in plasma cholesterol concentrations 27068 2.5.1.21 RPR107393 reduction of plasman cholesterol concentrations 27068 2.5.1.21 RPR107393 - 27068 2.5.1.21 RPR107393 inhibition of cholesterol biosynthesis and reduced plasma total cholesterol levels 27068 2.5.1.21 simvastatin - 2311 2.5.1.21 SMFC a tetrapeptide 212885 2.5.1.21 SPHS a tetrapeptide, slight inhibition 212893 2.5.1.21 squalestatin hypolipidemic effects but potential toxicity because of high levels of urinary dicarboxylic acid 5340 2.5.1.21 T-91485 - 155450 2.5.1.21 TAK-475 - 24427 2.5.1.21 Urea loss of 81% activity at 2 M, 50% at 1 M 116 2.5.1.21 WHQW a tetrapeptide 212887 2.5.1.21 YGPW a tetrapeptide 212889 2.5.1.21 YM-53601 decrease of non-high-density lipoprotein cholesterol 19111 2.5.1.21 YM-53601 reduction of non-high-density lipoprotein cholesterol concentrations 19111 2.5.1.21 YM-53601 - 19111 2.5.1.21 zaragozic acid IC50 0.7 nM 9625 2.5.1.21 zaragozic acid competitive to farnesyl diphosphate 9625 2.5.1.21 zaragozic acid hypolipidemic effects but potential toxicity because of high levels of urinary dicarboxylic acid 9625 2.5.1.21 zaragozic acid - 9625 2.5.1.21 zaragozic acid decrease in plasma cholesterol 9625 2.5.1.21 zaragozic acid competitive type of inhibition 9625 2.5.1.21 zaragozic acid potent inhibitor 9625 2.5.1.21 zaragozic acid A 0.04 mM 8684 2.5.1.21 zaragozic acid A inhibition of squalene synthase. Administration also significantly increases the rate of degradation of hepatic low density lipoprotein receptor protein, and increases proprotein convertase subtilisin/kexin type 9 mRNA and protein levels in concert with an increase in hepatic low density lipoprotein receptor mRNA levels, low density lipoprotein turnover, and decreases in serum cholesterol levels 8684 2.5.1.21 zaragozic acid A pH 7.2, 37°C 8684 2.5.1.21 zaragozic acid A is a potent inhibitor of mammalian SSN and also a competitive inhibitor of recombinant Leishmania donovani SSN, 50% inhibition at 100 nM 8684 2.5.1.21 zaragozic acid A enzyme binding induces a local conformational change in the substrate binding site, and its C-6 acyl group also extends over to the cofactor binding cavity, enzyme-inhibitor binding structure and thermodynamics, detailed overview 8684 2.5.1.21 zaragozic acid A - 8684 2.5.1.21 [(1R,5R)-7-chloro-1-(2-methylpropyl)-2-oxo-5-phenyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88670 2.5.1.21 [(1R,5S)-1-benzyl-7-chloro-5-(2-chlorophenyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88669 2.5.1.21 [(1R,5S)-5-(2-bromophenyl)-7-chloro-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88671 2.5.1.21 [(1R,5S)-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88666 2.5.1.21 [(1R,5S)-5-(2-chlorophenyl)-7-fluoro-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88665 2.5.1.21 [(1R,5S)-5-(2-chlorophenyl)-7-methyl-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88664 2.5.1.21 [(1R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88673 2.5.1.21 [(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88668 2.5.1.21 [(1R,5S)-7-chloro-5-(2-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88662 2.5.1.21 [(1R,5S)-7-chloro-5-(2-methoxyphenyl)-1-(2-methylpropyl)-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid - 88672 2.5.1.21 [(4R,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetic acid - 88654 2.5.1.21 [(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetic acid - 88657 2.5.1.21 [(4S,6R)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetic acid - 88656 2.5.1.21 [(4S,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetic acid - 88655 2.5.1.21 [(6S)-8-chloro-6-(2,3-dimethoxyphenyl)-1-(propan-2-yl)-6,10b-dihydro-1H,4H-[2]benzoxepino[4,5-c][1,2]oxazol-4-yl]acetic acid - 88661